Efficacy will be defined as renal allograft survival 6 months following treatment for AMR. Renal allograft loss will be defined as either (1) subject death, (2) return to dialysis for greater than 30 days, or (3) re-transplantation. 6 month [clinicaltrials_resource:d70d347c8d25a9c48bba79afd2cc3ce8]
Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Efficacy will be defined as renal allograft survival 6 months following treatment for AMR. Renal allograft loss will be defined as either (1) subject death, (2) return to dialysis for greater than 30 days, or (3) re-transplantation. 6 month [clinicaltrials_resource:d70d347c8d25a9c48bba79afd2cc3ce8]
Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
Bio2RDF identifier
d70d347c8d25a9c48bba79afd2cc3ce8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d70d347c8d25a9c48bba79afd2cc3ce8
measure [clinicaltrials_vocabulary:measure]
Efficacy will be defined as re ...... ys, or (3) re-transplantation.
time frame [clinicaltrials_vocabulary:time-frame]
description
Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
identifier
clinicaltrials_resource:d70d347c8d25a9c48bba79afd2cc3ce8
title
Efficacy will be defined as re ...... 3) re-transplantation. 6 month
@en
type
label
Efficacy will be defined as re ...... d347c8d25a9c48bba79afd2cc3ce8]
@en